Biology and clinical application of CAR T cells for B cell malignancies

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

(2016) Joseph A. Fraietta et al.   BLOOD

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors

(2016) Xiaojun Liu et al.   CANCER RESEARCH

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

(2016) Kole T. Roybal et al.   CELL

274. One-Step Generation of Universal CAR T Cells

(2016) Justin Eyquem et al.   MOLECULAR THERAPY

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

(2015) Zeguo Zhao et al.   CANCER CELL

Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies

(2015) X Wang et al.   CANCER GENE THERAPY

CAR therapy: the CD19 paradigm

(2015) Michel Sadelain   JOURNAL OF CLINICAL INVESTIGATION

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Large-scale Clinical-grade Retroviral Vector Production in a Fixed-Bed Bioreactor

(2015) Xiuyan Wang et al.   JOURNAL OF IMMUNOTHERAPY

Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy

(2015) Sebastian Kobold et al.   JNCI-Journal of the National Cancer Institute

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

The pharmacology of second-generation chimeric antigen receptors

(2015) Sjoukje J. C. van der Stegen et al.   NATURE REVIEWS DRUG DISCOVERY

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

(2015) E. Sotillo et al.   Cancer Discovery

Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy

(2015) Sebastian Kobold et al.   JNCI-Journal of the National Cancer Institute

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

(2013) D. T. Teachey et al.   BLOOD

Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity

(2013) C. Ankri et al.   JOURNAL OF IMMUNOLOGY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

(2013) V. D. Fedorov et al.   Science Translational Medicine

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

(2013) G. L. Beatty et al.   Cancer Immunology Research

Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo

(2013) E. Lanitis et al.   Cancer Immunology Research

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

(2012) H. J. Pegram et al.   BLOOD

CAR T cells transform to trucks: chimeric antigen receptor–redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer

(2012) Markus Chmielewski et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor

(2012) Megan E. Prosser et al.   MOLECULAR IMMUNOLOGY

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

(2012) Christopher C Kloss et al.   NATURE BIOTECHNOLOGY

How do CARs work?

(2012) Marco L. Davila et al.   OncoImmunology

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

(2011) R. J. Brentjens et al.   BLOOD

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

(2010) Michael C. Jensen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

(2010) J. N. Kochenderfer et al.   BLOOD

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

The promise and potential pitfalls of chimeric antigen receptors

(2009) Michel Sadelain et al.   CURRENT OPINION IN IMMUNOLOGY

Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy

(2009) Daniel Hollyman et al.   JOURNAL OF IMMUNOTHERAPY

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

(2008) B. G. Till et al.   BLOOD